Core Viewpoint - The company has made significant progress in its operations, including the transfer of equity stakes, approval for new facilities, and advancements in clinical trials and smart factory construction. Group 1: Financial and Shareholder Information - The company plans to distribute a cash dividend of 1.50 yuan per 10 shares to all shareholders, based on a total of 504,248,738 shares [1] - There has been no change in the controlling shareholder or actual controller during the reporting period [1] Group 2: Major Corporate Actions - The company has approved the public transfer of 80% equity in Jiangxi Boya Xinha Pharmaceutical Co., Ltd., with a revised listing price of 158.1655 million yuan [3][4] - The company received approval to establish a single plasma collection station in Dalat Qi, Inner Mongolia [5] - The company obtained clinical trial approval for subcutaneous immunoglobulin and a supplementary drug application for intravenous immunoglobulin [6] Group 3: Operational Developments - The construction of the blood product smart factory is progressing well, with the main structure completed and various installations underway [6] - The company aims to set high standards for the smart factory project, positioning it as a benchmark in the biopharmaceutical industry [6] Group 4: Shareholder Actions - The controlling shareholder, China Resources Pharmaceutical Holdings Co., Ltd., has completed a share buyback plan, acquiring a total of 6,050,900 shares, representing 1.2% of the total share capital [7][8]

Core Viewpoint - The supervisory board of China Resources Boya Bio-Pharmaceutical Group Co., Ltd. confirmed the legality and compliance of the company's 2025 semi-annual report and related proposals, ensuring no misleading statements or omissions [1][2][3]. Group 1: Supervisory Board Meeting - The 12th meeting of the 8th supervisory board was held on August 21, 2025, with all three supervisors present, confirming compliance with relevant laws and regulations [1]. - The supervisory board approved the procedures for reviewing the 2025 semi-annual report, affirming its authenticity and completeness [1][2]. Group 2: Profit Distribution Proposal - The supervisory board agreed that the profit distribution proposal for the 2025 semi-annual report complies with regulatory guidelines and the company's profit distribution policy [2]. - The proposal will be submitted for review at the company's first extraordinary general meeting of 2025 [2]. Group 3: Fund Management - The supervisory board expressed approval of the management of the special account for raised funds, confirming compliance with relevant regulations [2][3]. - The report on the storage and use of raised funds for the first half of 2025 was deemed accurate and complete by the supervisory board [2][3]. Group 4: Use of Bank Acceptance Bills - The supervisory board approved the proposal to use bank acceptance bills to pay for project funding and to replace the funds with raised capital [3].

Meeting Information - The company will hold its first extraordinary general meeting of shareholders in 2025 on September 12, 2025, at 14:00 [1] - The meeting will be conducted both in-person and via online voting [1][2] - The record date for shareholders to attend the meeting is September 4, 2025 [2] Voting Procedures - Shareholders can choose to vote either in person or through online platforms provided by the Shenzhen Stock Exchange [2][4] - Only one voting method can be selected by each shareholder, and duplicate votes will be disregarded [2] - Detailed procedures for online voting are available in the attached documents [6] Attendance Requirements - Corporate shareholders must present a copy of their business license, a power of attorney, and identification [3] - Individual shareholders must provide personal identification and proof of shareholding [3] - Remote shareholders can register via mail or phone before the registration deadline [3] Agenda Items - The meeting will review proposals that have been approved by the company's board of directors [2] - Specific details regarding the proposals can be found on the designated information disclosure website [2]

Group 1 - The company achieved a revenue of 1.008 billion yuan in the first half of 2025, representing a year-on-year growth of 12.51%, and a net profit attributable to shareholders of 225 million yuan [1] - The company plans to distribute a cash dividend of 1.5 yuan per 10 shares (including tax) [1] - The company owns 21 plasma collection stations, with 20 currently operational, and collected 320.39 tons of raw plasma, a year-on-year increase of 7.2% [1] Group 2 - The company’s R&D investment for the first half of the year was 44.7189 million yuan, an increase of 2.12% year-on-year [2] - The successful approval of 10% immunoglobulin for market launch marks the company as the third in China to have this product, enhancing the comprehensive utilization rate of plasma [2] - The blood products market in China is projected to reach approximately 60 billion yuan in 2024 and is expected to grow to 100 billion yuan by 2030 [2]

Core Viewpoint - The company has announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 1.50 yuan per 10 shares, with no bonus shares or capital increase [1][4][5]. Summary by Sections Profit Distribution Plan - The profit distribution plan includes a cash dividend of 80,679,798.08 yuan, with total distributable profits amounting to 2,886,930,513.07 yuan, based on the parent company's financial statements [2][3]. - The total distributable profit as of June 30, 2025, is 2,810,078,733.67 yuan, considering the lower of the profits available for distribution from the consolidated and parent company financial statements [2][3]. Approval Process - The audit committee and the board of directors have reviewed and approved the profit distribution plan, which will be submitted for approval at the company's first extraordinary general meeting of 2025 [1][2][4]. Compliance and Justification - The profit distribution plan complies with relevant regulations, including the Company Law and the guidelines for cash dividends, ensuring it aligns with the company's long-term return strategy for shareholders [4][5]. - The plan reflects the company's operational performance and future funding needs while ensuring reasonable returns for shareholders [4][5]. Industry Context - The blood products sector is characterized by high demand and stringent regulatory oversight, making licenses for blood product companies scarce. This has led to a favorable market environment for existing players [5]. - The pharmaceutical industry in China is experiencing rapid growth, driven by economic development and healthcare reforms, presenting significant opportunities for companies in this sector [5].

具体内容详见同日在巨潮资讯网（网址：http://www.cninfo.com.cn）披露的 《公司 2025 年半年度报告》《公司 2025 年半年度报告摘要》。 证券代码：300294 证券简称：博雅生物 公告编号：2025-055 华润博雅生物制药集团股份有限公司 第八届董事会第十五次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 华润博雅生物制药集团股份有限公司（以下简称公司）第八届董事会第十五 次会议于 2025 年 8 月 11 日以邮件及通讯方式通知，并于 2025 年 8 月 21 日在公 司会议室以现场加通讯表决的方式召开。会议应参加表决董事 7 人，实参加表决 董事 7 人。会议由董事长邱凯先生主持，公司监事及高级管理人员列席了会议。 本次会议符合《中华人民共和国公司法》《中华人民共和国证券法》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》及《公司章程》等相关规定。经充分讨论，审议 通过了以下议案。 二、董事会会议审议情况 经审议，董事会认为 ...

Core Insights - The company reported a revenue of 1,007,772,869.56 yuan for the first half of 2025, reflecting a year-on-year growth of 12.51% [2] - The net profit attributable to shareholders decreased to 225,340,907.90 yuan, representing a year-on-year decline of 28.68% [2] Financial Performance - Revenue for the first half of 2025: 1,007.77 million yuan, up 12.51% compared to the previous year [2] - Net profit for the same period: 225.34 million yuan, down 28.68% year-on-year [2]

Core Viewpoint - Boya Bio announced the approval of multiple proposals, including the full text and summary of the 2025 semi-annual report, during the 12th meeting of the 8th Supervisory Board [2] Group 1 - The 8th Supervisory Board of Boya Bio held its 12th meeting on August 22 [2] - The meeting resulted in the approval of the proposal regarding the 2025 semi-annual report [2]

（文章来源：证券日报） 证券日报网讯 8月22日晚间，博雅生物发布公告称，公司第八届董事会第十五次会议审议通过了《关于 公司2025年半年度报告全文及摘要的议案》等多项议案。 ...

（文章来源：证券日报） 证券日报网讯 8月22日晚间，博雅生物发布关于2025年半年度利润分配预案的公告称，公司本次2025年 半年度利润分配预案为：以504，248，738股为基数，拟向全体股东每10股派发现金红利1.50元（含 税）。 ...